Osteoporosis and Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD): Back to Basics.
暂无分享,去创建一个
[1] P. Miller,et al. The CKD‐MBD Syndrome: Hysteresis in PTH Involvement and PTH Administration for Its Management , 2020, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[2] J. Compston,et al. Defining Very High Fracture Risk: Is FRAX Fit for Purpose? , 2020, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[3] W. Leslie,et al. Trabecular bone score in patients with chronic kidney disease , 2020, Osteoporosis International.
[4] P. Miller,et al. Current Understanding of Mineral and Bone Disorders of Chronic Kidney Disease and the Scientific Grounds on the Use of Exogenous Parathyroid Hormone in Its Management , 2020, Journal of bone metabolism.
[5] M. Allen,et al. Elevations in Cortical Porosity Occur Prior to Significant Rise in Serum Parathyroid Hormone in Young Female Mice with Adenine-Induced CKD , 2019, Calcified Tissue International.
[6] M. Fusaro,et al. How and when to assess bone mineral density and bone quality in chronic kidney disease patients? , 2019, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[7] M. Pazianas. Bones, heart and the new anabolic agent romosozumab , 2019, Postgraduate Medical Journal.
[8] Nadine Kaesler,et al. Sclerostin in chronic kidney disease-mineral bone disorder think first before you block it! , 2019, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[9] N. Lane. Glucocorticoid-Induced Osteoporosis: New Insights into the Pathophysiology and Treatments , 2019, Current Osteoporosis Reports.
[10] T. Nickolas,et al. Rethinking Bone Disease in Kidney Disease , 2018, JBMR plus.
[11] P. Kerr,et al. Gonadal Hormones in the Pathogenesis and Treatment of Bone Health in Patients with Chronic Kidney Disease: a Systematic Review and Meta-Analysis , 2018, Current Osteoporosis Reports.
[12] T. Nickolas,et al. Management of Osteoporosis in CKD. , 2018, Clinical journal of the American Society of Nephrology : CJASN.
[13] P. Ebeling,et al. Deterioration of Cortical Bone Microarchitecture: Critical Component of Renal Osteodystrophy Evaluation , 2018, American Journal of Nephrology.
[14] T. Nickolas. The Quest for Better Biomarkers of Bone Turnover in CKD. , 2018, Journal of the American Society of Nephrology : JASN.
[15] G. Elder,et al. The trabecular bone score is associated with bone mineral density, markers of bone turnover and prevalent fracture in patients with end stage kidney disease , 2018, Osteoporosis International.
[16] J. Carrero,et al. Cinacalcet use and the risk of cardiovascular events, fractures and mortality in chronic kidney disease patients with secondary hyperparathyroidism , 2018, Scientific Reports.
[17] James M. Eales,et al. Tick-Tock Chimes the Kidney Clock – from Biology of Renal Ageing to Clinical Applications , 2018, Kidney and Blood Pressure Research.
[18] J. Craig,et al. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD). , 2018, The Cochrane database of systematic reviews.
[19] R. Eastell,et al. Use of bone turnover markers in postmenopausal osteoporosis. , 2017, The lancet. Diabetes & endocrinology.
[20] S. Sprague,et al. Extended-release calcifediol for secondary hyperparathyroidism in stage 3-4 chronic kidney disease , 2017, Expert review of endocrinology & metabolism.
[21] Mary B Leonard,et al. Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters. , 2017, Kidney international.
[22] Andreja Marn Pernat,et al. Bone mineral disturbances in patients with chronic kidney disease stage 5 not yet on dialysis. , 2017, Clinical Nephrology.
[23] S. Moe. Renal Osteodystrophy or Kidney-Induced Osteoporosis? , 2017, Current Osteoporosis Reports.
[24] J. Kanis,et al. FRAX Update. , 2017, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.
[25] A. Rule,et al. The Substantial Loss of Nephrons in Healthy Human Kidneys with Aging. , 2017, Journal of the American Society of Nephrology : JASN.
[26] D. Davenport,et al. Two-year cortical and trabecular bone loss in CKD-5D: biochemical and clinical predictors , 2017, Osteoporosis International.
[27] H. Kimura-Suda,et al. Efficacy and safety of osteoporosis medications in a rat model of late-stage chronic kidney disease accompanied by secondary hyperparathyroidism and hyperphosphatemia , 2017, Osteoporosis International.
[28] C. Christiansen,et al. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial. , 2016, JAMA.
[29] S. Moe,et al. Diagnostic Accuracy of Bone Turnover Markers and Bone Histology in Patients With CKD Treated by Dialysis. , 2016, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[30] C C Glüer,et al. Trabecular bone score (TBS) as a new complementary approach for osteoporosis evaluation in clinical practice. , 2015, Bone.
[31] S. Jamal,et al. Teriparatide and bone turnover and formation in a hemodialysis patient with low-turnover bone disease: a case report. , 2015, American Journal of Kidney Diseases.
[32] A. Cheung,et al. Rationale and Approaches to Phosphate and Fibroblast Growth Factor 23 Reduction in CKD. , 2015, Journal of the American Society of Nephrology : JASN.
[33] C. Chiang,et al. Hypocalcemia Post Denosumab in Patients with Chronic Kidney Disease Stage 4-5 , 2015, American Journal of Nephrology.
[34] S. Boonen,et al. Renal safety in patients treated with bisphosphonates for osteoporosis: A review , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[35] K. Hruska,et al. Pathophysiology of Chronic Kidney Disease Mineral Bone Disorder (CKD‐MBD) , 2013 .
[36] P. Miller,et al. Skeletal effects of primary hyperparathyroidism: bone mineral density and fracture risk. , 2013, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.
[37] J. Bacchetta,et al. Bone microarchitecture is more severely affected in patients on hemodialysis than in those receiving peritoneal dialysis. , 2012, Kidney international.
[38] S. Cummings,et al. Effects of denosumab on fracture and bone mineral density by level of kidney function , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[39] Jacques P. Brown,et al. Effects of denosumab on bone histomorphometry: The FREEDOM and STAND studies , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[40] C. Cooper,et al. Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis , 2010, Therapeutics and clinical risk management.
[41] H. Macdonald,et al. Changes in trabecular and cortical bone microarchitecture at peripheral sites associated with 18 months of teriparatide therapy in postmenopausal women with osteoporosis , 2010, Osteoporosis International.
[42] P. Miller. Fragility fractures in chronic kidney disease: An opinion-based approach , 2009, Cleveland Clinic Journal of Medicine.
[43] M. Almeida,et al. Increased Lipid Oxidation Causes Oxidative Stress, Increased Peroxisome Proliferator-activated Receptor-γ Expression, and Diminished Pro-osteogenic Wnt Signaling in the Skeleton* , 2009, The Journal of Biological Chemistry.
[44] P. Miller. The role of bone biopsy in patients with chronic renal failure. , 2008, Clinical journal of the American Society of Nephrology : CJASN.
[45] A. Levin,et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. , 2007, Kidney international.
[46] G. Eknoyan,et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). , 2006, Kidney international.
[47] E. Schwartz,et al. Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment , 2006, Osteoporosis International.
[48] G. Eknoyan,et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). , 2005, Kidney international.
[49] G. Eknoyan,et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[50] R. Turner,et al. Printed in U.S.A. Copyright © 1997 by The Endocrine Society The Effects of Programmed Administration of Human Parathyroid Hormone Fragment (1–34) on Bone Histomorphometry and Serum Chemistry in Rats* , 2022 .
[51] Claus Christiansen,et al. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. , 1994, World Health Organization technical report series.
[52] E. Ritz,et al. Calcium metabolism in early chronic renal failure: implications for the pathogenesis of hyperparathyroidism. , 1991, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[53] E. Ritz,et al. Bone histology in incipient and advanced renal failure. , 1976, Kidney international.